ZyVersa Therapeutics to Participate in a Fireside Chat at
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease,...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-01, 21:29
